Sensei Biotherapeutics, Inc. (SNSE): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNSE Stock Price Chart Interactive Chart >
SNSE Price/Volume Stats
|Current price||$1.39||52-week high||$5.00|
|Prev. close||$1.43||52-week low||$1.30|
|Day high||$1.46||Avg. volume||34,059|
|50-day MA||$1.48||Dividend yield||N/A|
|200-day MA||$1.73||Market Cap||42.70M|
Sensei Biotherapeutics, Inc. (SNSE) Company Bio
Sensei Biotherapeutics, Inc. operates as a clinical-stage immunotherapy company. The Company focuses in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Sensei Biotherapeutics serves customers in the United States.
Most Popular Stories View All
SNSE Latest News Stream
|Loading, please wait...|
SNSE Latest Social Stream
View Full SNSE Social Stream
Latest SNSE News From Around the Web
Below are the latest news stories about SENSEI BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate SNSE as an investment opportunity.
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo® (cemiplimab). The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo® in a Phase 1/2 trial in solid tumors. Sensei is on track to
Sensei Biotherapeutics (SNSE) said it will close its research site in Boston and reduce its total workforce by ~40%.The company added that it will focus resources on its key…
An immunotherapy startup that pulled off a $133 million IPO last year is shuttering its Boston research operations and laying off about 40% of its workforce.
Sensei Biotherapeutics Inc (NASDAQ: SNSE) announced a streamlining and realignment of resources. The company will close its Boston research site and reduce its workforce by approximately 40% to extend Sensei's estimated cash runway into the second half of 2025 versus Q1 of 2025 expected earlier. The company will maintain its Rockville, Maryland research facility, where antibody discovery and production in support of its lead program SNS-101 and other TMAb programs is conducted while maintaining
- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses -- Continued focus on development of TMAb™ programs; IND submission for lead antibody SNS-101 anticipated in or prior to April 2023 -- Cash runway extended into the second half of 2025 -BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patient
SNSE Price Returns